Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics

Summary Development of advanced and high-throughput methods to study variability in human genes means we can now use pharmacogenomic analysis not only to predict response to treatment but also to assess the toxic action of drugs on normal cells (so-called toxicogenomics). This technological progress...

Full description

Saved in:
Bibliographic Details
Published inThe lancet oncology Vol. 12; no. 12; pp. 1151 - 1161
Main Authors Cavaletti, Guido, Prof, Alberti, Paola, MD, Marmiroli, Paola, MD
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.11.2011
Elsevier Limited
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Summary Development of advanced and high-throughput methods to study variability in human genes means we can now use pharmacogenomic analysis not only to predict response to treatment but also to assess the toxic action of drugs on normal cells (so-called toxicogenomics). This technological progress could enable us to identify individuals at high and low risk for a given side-effect. Pharmacogenomics could be very useful for stratification of cancer patients at risk of developing chemotherapy-induced peripheral neurotoxicity, one of the most severe and potentially permanent non-haematological side-effects of modern chemotherapeutic agents. However, study data reported so far are inconsistent, which suggests that methodological improvement is needed in clinical trials to obtain reliable results in this clinically relevant area.
ISSN:1470-2045
1474-5488
DOI:10.1016/S1470-2045(11)70131-0